$599
UPDATED FENIX Analysis: SGLT2i HF CVOTs and Stopping Early Scenarios
Based on the recent AZ announcement for the initiation of a Farxiga HFpEF Ph3b study, FENIX has updated its previous SGLT2i heart failure CVOT tale-of-the-tape analysis (published June 1, 2018) and projected timeline for filings and launches.